Articles By Cyndi Root

31. Takeda Restructures Manufacturing, Shifts Leuplin Production To Osaka Site 12/3/2014

    Takeda is restructuring its manufacturing efforts, moving the production of Leuplin to its Osaka Plant in the Osaka Prefecture, Japan. The company announced the move in a press release, stating that it aims to optimize its global manufacturing network.

32. Trimel Licenses Natesto For Hypogonadism To Endo For Marketing 12/2/2014

    Trimel Pharmaceuticals has licensed Natesto to Endo International for marketing in the U.S. and Mexico. The companies announced the deal in a press release, stating that Natesto is a nasal gel, Food and Drug Administration (FDA)-approved for men with hypogonadism to replace testosterone.

33. Merck, NewLink Genetics Partner On Investigational Ebola Vaccine 11/26/2014

    Merck and NewLink Genetics Corporation have partnered to develop NewLink’s investigational rVSV-EBOV (Ebola) vaccine candidate.

34. Patheon To Manufacture Anthera's Liprotamase For Exocrine Pancreatic Insufficiency 11/26/2014

    Anthera Pharmaceuticals has contracted with Patheon, a contract development and manufacturing organization (CDMO), to manufacture Sollpura (liprotamase).

35. AbbVie Acquires API Facility In Singapore 11/26/2014

    AbbVie joins other major pharmaceutical companies in locating facilities in Singapore, an island country with a growing pharmaceutical presence.

36. Lonza To Manufacture Sunshine Biopharma's Anti-Cancer Compound 11/25/2014

    Sunshine Biopharma and Lonza have struck a manufacturing deal. Lonza has agreed to manufacture Sunshine’s lead anti-cancer drug, Adva-27a.

37. Amgen Terminates Rilotumumab Clinical Studies In Advanced Gastric Cancer 11/25/2014

    Amgen has announced that it is terminating all Amgen-sponsored clinical studies of rilotumumab in advanced gastric cancer.

38. New And Updated Drug Shortages List 11/18/14 11/24/2014

    The Food and Drug Administration (FDA) has published its new and updated Drug Shortages through 11/18/14.

39. Knight Sells Tropical Disease Priority Review Voucher To Gilead 11/24/2014

    Knight Therapeutics has sold its Neglected Tropical Disease Priority Review Voucher (PRV) to Gilead. Knight announced the sale in a press release, stating that it received the PRV in March 2014 with the approval of Impavido (miltefosine) for treatment of patients with visceral, mucosal, and cutaneous leishmaniasis.

40. MRC Technology Forms Consortium To Repurpose Shelved Drugs For Brain Diseases 11/21/2014

    MRC Technology, a technology transfer organization, has formed a consortium to find shelved drugs and re-explore their potential to treat brain diseases.